Investors
Some useful information for our future investors:
- LIMSA FC has patented the next generation of local hemostatic agents for use in surgery and wound healing. The Technology developed by LIMSA is safe, highly effective, affordable and will have large availability
- LIMSA FC is developing the first non absorbable compound to control bladder hematuria and provide better quality of leaving to cancer patients undergoing radiation
- LIMSA FC develops technology that will allow Ophthalmologists to paractice safe and effective procedures to revert retonopathy and avoid Diabetic Blindness
- LIMSA FC developes bacteriostatic drugs with the potential to susbtitute antibiotics in the treatment of ear, throat and nose infections.
